Curis (CRIS) Q4 2025 earnings review
Mirage Profit: One-Time Gain Masks Transformation to Zero-Revenue Biotech
Curis reported a surprise $19.4M Q4 Net Income, but this is a purely accounting artifact. The company sold its Erivedge royalty rights, booking a $27.2M non-cash gain from liability extinguishment and permanently eliminating its only revenue stream. Consequently, Q4 revenue collapsed 66% YoY to $1.1M and will drop to zero in 2026. The real story is survival: a January 2026 PIPE financing provides up to $80.8M, extending the cash runway into H2 2027 and shifting the entire investment thesis to the clinical execution of emavusertib in PCNSL and CLL.
🐂 Bull Case
The January 2026 PIPE and Erivedge royalty sale eliminate the immediate bankruptcy risk that plagued the company throughout 2025, extending the cash runway into H2 2027 and allowing full focus on clinical execution.
Data presented at SNO showed a 100% ORR (5 of 5) in BTKi-naive PCNSL patients and 37% ORR in BTKi-experienced patients, validating emavusertib's potential for accelerated approval in an indication with zero approved therapies.
🐻 Bear Case
By selling the Erivedge asset to Oberland Capital, Curis has eliminated its only source of non-dilutive capital, reversing its revenue trend to permanent zero and becoming entirely dependent on future equity raises and binary clinical outcomes.
The $80.8M PIPE is heavily tranched. Only $20.2M was received upfront; the remainder is locked behind Series A, B, and C warrants exercisable at $0.75/share, ensuring significant future equity dilution and milestone risk.
⚖️ Verdict: ⚪
Neutral. The financing secures survival and extends the runway to H2 2027, which is a massive positive. However, the complete forfeiture of Erivedge revenue and the heavily dilutive warrant structure of the new PIPE cap the upside. It is now a pure-play, high-risk binary clinical bet.
Key Themes
Emavusertib Regulatory Path in PCNSL
The TakeAim Lymphoma study remains the company's fastest path to market. The updated SNO data is highly compelling, showing a 100% ORR in BTKi-naive patients and a 123-day median treatment duration for responders. With Orphan Drug Designation secured from both the FDA and EMA, management's strategy to use this single-arm study for accelerated approval filings is accelerating.
Strategic Expansion into Large CLL Market
Curis initiated an open-label Phase 2 study of emavusertib combined with zanubrutinib in CLL. This tests a specific product innovation: dual blockade of the NF-kB driver by inhibiting both TLR (via emavusertib) and BCR (via zanubrutinib) pathways. If successful, this could shift CLL from chronic, lifelong BTKi treatment to a time-limited treatment paradigm by achieving deeper MRD-negative remissions.
AML Triplet Study Showing Early Promise
Initial data at ASH for the frontline AML triplet (emavusertib + azacitidine + venetoclax) showed that 5 out of 8 evaluable patients (62.5%) achieved MRD conversion. While early, this validates the drug's mechanism in deepening responses for high-risk leukemia patients.
Milestone-Dependent Cash Infusion Contradicts Stable Runway Narrative
While management touts a cash runway extending to H2 2027, the underlying data contradicts a stress-free capital position. The $80.8M PIPE requires the exercise of Series B warrants, which are strictly tied to a clinical milestone (dosing the 5th CLL patient). If enrollment delays occur—a historical issue for the company—this critical funding tranche could be severely delayed, exposing the company to renewed liquidity risk.
Erivedge Divestiture Creates Permanent Revenue Void
The sale of the Erivedge royalty stream to TPC Investments for $2.5M upfront and liability release marks a reversing trend from a stable ~$10M/year top line to $0. This segment grew significantly below the company average (down 66% in Q4 to $1.1M) as it was wound down. Future operations are now 100% reliant on cash burn.
Ultra-Rare Disease Enrollment Constraints
Prior quarters highlighted a painfully slow enrollment pace for PCNSL (projected at 1 patient per site per year). The current materials note 9 patients discontinued treatment prior to completing 1 cycle due to adverse events, disease progression, or hospice. High attrition rates in a hard-to-enroll indication could threaten accelerated approval timelines.
Macro Regulatory Uncertainty
Management has previously acknowledged that broader FDA unpredictability poses a macro risk. While Curis has alignment for a single-arm accelerated pathway in PCNSL, changing FDA stances on accelerated approvals in oncology remain an external headwind that requires monitoring.
Other KPIs
Decelerating. R&D spending fell 27% YoY from $38.6M in FY24. The Q4 run-rate dropped even sharper to $5.8M (vs $9.0M in 24Q4). This demonstrates aggressive cost-cutting in clinical, manufacturing, and consulting lines to artificially stretch the cash runway prior to the January 2026 financing.
A one-time, non-cash gain recognized upon the sale of Erivedge and the extinguishment of future royalty obligations to Oberland. This completely distorted Q4 Net Income to a positive $19.4M, masking an underlying operating loss of roughly $8.7M for the quarter.
Guidance
Accelerating/Improving significantly. Previous guidance (from Q3) projected cash lasting only 'into 2026'. The combination of the Dec 31 cash balance ($5.1M), the initial $20.2M PIPE draw, and the expected $20.2M Series B warrant exercise upon 5th CLL patient dosing extends operations by nearly 18 months.
Reversing. Due to the Erivedge transaction closing in November 2025, the company will generate zero royalty revenue moving forward, completing its transition into a pure clinical-stage entity.
Key Questions
Series B Warrant Execution Certainty
Given that the Series B warrants are tied to dosing the 5th patient in the CLL trial, what is the exact timeline for reaching this milestone, and are there fallback capital contingencies if enrollment lags?
PCNSL Enrollment and Attrition
With 9 patients unable to complete a single cycle in the PCNSL study due to disease progression or AE, how is this high attrition rate factoring into the 30-40 patient targeted enrollment timeline for accelerated approval?
AML Triplet Next Steps
Now that 62.5% of patients showed MRD conversion in the frontline AML triplet study, what are the specific regulatory or clinical next steps required to advance this into a registrational setting?